1-20 of 1,616 results for subject:"Medical treatments"
Librarians' tools
- Search time
- 0.304 seconds
- Solr query time
- 0.008 seconds
- Search query
- subject:"Medical treatments"
- We searched for
- subject_t:"Medical treatments" OR subject_ses:91973
Type
House
Session
Month
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health what steps his Department has taken to ensure that primary care trusts in the South West comply with National Institute for Health and Clinical Excellence recommendations on computerised cognitive behavioural therapy for mild and moderate depression; what estimate his Department has made...
To ask the Secretary of State for Health what steps his Department has taken to ensure that primary care trusts in the South West comply with National Institute for Health and Clinical Excellence recommendations on computerised cognitive behavioural therapy for mild and moderate depression; what estimate his Department has made...
To ask Her Majesty's Government how they intend to further their focus on improving the long-term health of Gulf War veterans, following their initial response to the report of the Research Advisory Committee on Gulf War Veterans' Illnesses, mandated by the United States Congress and published on 17 November.
To ask Her Majesty's Government how they intend to further their focus on improving the long-term health of Gulf War veterans, following their initial response to the report of the Research Advisory Committee on Gulf War Veterans' Illnesses, mandated by the United States Congress and published on 17 November.
To ask Her Majesty's Government when they expect to respond in detail to the findings of the Research Advisory Committee on Gulf War Veterans' Illnesses, mandated by the United States Congress and published on 17 November, with particular reference to new policy for research and redress for United Kingdom veterans...
To ask Her Majesty's Government when they expect to respond in detail to the findings of the Research Advisory Committee on Gulf War Veterans' Illnesses, mandated by the United States Congress and published on 17 November, with particular reference to new policy for research and redress for United Kingdom veterans...
To ask the Secretary of State for Health (1) what guidance is provided to healthcare professionals to prevent prescribing and dispensing errors in relation to immunosuppressant therapies;
To ask the Secretary of State for Health (1) what guidance is provided to healthcare professionals to prevent prescribing and dispensing errors in relation to immunosuppressant therapies;
| Category of error | Number of reported errors |
| Prescribing | 253 |
| Preparation of medicines in all locations/dispensing in a pharmacy | 242 |
| Administration/supply of a medicine from a clinical area | 520 |
| Total | 1,015 |
| Note: The following immunosuppressant medicines were included within the incident report: Advagraf, Alemtuzumab, Azathiaprine, Basiliximab, Cellcept, Ciclosporin, Daclizumab, Imuran, Mabcampath, Mabthera, Mycophenolate, Myfortic, Neoral, Prograf, Rapamune, Rituximab, Sandimmun, Simulect, Sirolimus, Tacrolimus, Zenapax. |
(2) how many (a) prescribing and (b) dispensing errors of immunosuppressant therapies have been recorded in each of the last five years; if he will place in the Library a copy of the records; and if he will make a statement.
(2) how many (a) prescribing and (b) dispensing errors of immunosuppressant therapies have been recorded in each of the last five years; if he will place in the Library a copy of the records; and if he will make a statement.
| Category of error | Number of reported errors |
| Prescribing | 253 |
| Preparation of medicines in all locations/dispensing in a pharmacy | 242 |
| Administration/supply of a medicine from a clinical area | 520 |
| Total | 1,015 |
| Note: The following immunosuppressant medicines were included within the incident report: Advagraf, Alemtuzumab, Azathiaprine, Basiliximab, Cellcept, Ciclosporin, Daclizumab, Imuran, Mabcampath, Mabthera, Mycophenolate, Myfortic, Neoral, Prograf, Rapamune, Rituximab, Sandimmun, Simulect, Sirolimus, Tacrolimus, Zenapax. |
To ask the Secretary of State for Health what steps his Department takes to protect patients from the risk posed by the varying bioequivalence of therapies used for the same indication; and if he will make a statement.
To ask the Secretary of State for Health what steps his Department takes to protect patients from the risk posed by the varying bioequivalence of therapies used for the same indication; and if he will make a statement.
To ask the Secretary of State for Health (1) what steps he plans to take to facilitate access to information on treatment choices for those with cancer;
To ask the Secretary of State for Health (1) what steps he plans to take to facilitate access to information on treatment choices for those with cancer;
(2) what plans he has to improve post-treatment support for cancer patients.
(2) what plans he has to improve post-treatment support for cancer patients.
To ask Her Majesty's Government what percentage of schools attended by children with diabetes do not have a policy for (a) advising staff how to supervise blood glucose monitoring (BGM); (b) how to carry out BGM; (c) how to supervise the taking of medication; and (d) how to give medication;...
To ask Her Majesty's Government what percentage of schools attended by children with diabetes do not have a policy for (a) advising staff how to supervise blood glucose monitoring (BGM); (b) how to carry out BGM; (c) how to supervise the taking of medication; and (d) how to give medication;...
That this House congratulates the National Rheumatoid Arthritis Society on its caring activities; notes the National Institute for Health and Clinical Excellence (NICE) Final Appraisal Document; is aware of the pain, and the medical and social problems, faced by people suffering from rheumatoid arthritis; further notes that effective treatment can save the NHS significant sums in the longer term; further notes that the NICE decision would deny 60,000 people with rheumatoid arthritis access to a range of anti-TNF drugs and could leave them facing high levels of pain, the possibility of more surgery and long-term disability; and therefore calls on the Government to ensure that anti-TNF drugs are available to rheumatoid arthritis sufferers according to their clinical needs.
That this House congratulates the National Rheumatoid Arthritis Society on its caring activities; notes the National Institute for Health and Clinical Excellence (NICE) Final Appraisal Document; is aware of the pain, and the medical and social problems, faced by people suffering from rheumatoid arthritis; further notes that effective treatment can...